Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma Meeting Abstract
| Authors: | Berdeja, J. G.; Oki, Y.; Patel, M. R.; Copeland, A.; Flinn, I.; Neelapu, S. S.; Viner, J.; Wang, J.; Gerecitano, J. F.; Younes, A. |
| Abstract Title: | Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901849 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.8537 |
| Notes: | Meeting Abstract: 8537 -- Source: Wos |
